Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Mylan's Lantus Rival Faces Fresh Attack

Sanofi Tries To Stop Biosimilar Via Supreme Court PTAB Review

Mar 02 2020

• By Brenda Sandburg

A law book with a gavel - Constitution — Sanofi Says Unconstitutional Status Of PTAB Judges Warrants Appeal of Lantus Ruling • Source: Shutterstock

Related Content

Sanofi Improperly Listed Lantus Patent In FDA's Orange Book, Appeals Court Finds

Feb 16 2020

'Super Dramatic' Ruling On PTAB Judges' Unconstitutional Status Will Have 'Limited Fallout'

Nov 05 2019

Patent Judges Could Get Congressional Fix After Federal Circuit Ruling

Nov 21 2019

Mylan/Biocon’s Insulin Glargine Would Get A Respite Under US Budget Legislation

Dec 18 2019

US Supreme Court Seems Poised To Allow Patent Holders More Judicial Review Options

Dec 10 2019

Biocon And Mylan's Fulphila And Insulin Plans On Track

Jan 27 2020

Related Companies

Sanofi

Viatris Inc.

Arthrex, Inc.

Smith & Nephew plc

Biocon, Ltd.

Additional Topics

Legal Issues Intellectual Property Biosimilars Policy BioPharmaceutical

More from Legal & IP

More from Generics Bulletin

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window